Our web chats are text based discussions. Anyone is welcome to join in the web chat.
You don’t have to be registered to join in. Simply type in your question.
Our expert will answer as many questions as possible in the allocated time. Questions are answered in the order received, although it may take a while for your question to appear ‘live’ on-screen, depending on where it falls in the queue.
If several questions are asked on the same topic, the speaker may summarise them. Questions and answers appear on the screen - you are not able to hear the chat; there is no video or sound.
Remember that the web chats are public and everyone can view your comments so do not submit information that you do not want others to see.
The web chats provide information only. They are not intended to replace a consultation with an appropriately qualified health professional.
We cannot guarantee that information provided by us through web chats will meet your health or medical requirements. If you are concerned about your health, contact your doctor.
By taking part in one of our web chats you acknowledge and agree that we will not be responsible for any claims, losses or damages (whether direct or indirect) arising out of, or relating to, the misuse of, or inappropriate reliance on, the contents or advice contained within the chats, except to the extent that such liability cannot be excluded by law.
Wednesday 6 July 2016, 12:00 - 13:00
Managing myelodysplastic syndromes (MDS) – from diagnosis to treatment
Myelodysplastic syndrome (MDS), or myelodysplasia, is a blood disorder that causes a drop in your number of healthy blood cells. MDS covers a spectrum of disorders from indolent (slow developing) to aggressive (that rapidly develop or change into leukaemia).
MDS can affect people of any age, but is most common in people over the age of 65. Only one in five people with MDS are younger than 50. For most people, symptoms are mild at first and slowly get worse. Sometimes you may even have no symptoms at all, but have had a blood test that shows there is a problem. The treatment of MDS is constantly evolving and new drugs are being tested all the time.
Our expert is consultant haematologist Dr Beth Payne who specialises in treating patients with myelodysplastic syndromes and bone marrow failure. She is also a Senior Clinical Researcher funded by the Wellcome Trust and The Leuka John Goldman Fellowship for future Science and runs a research laboratory studying the mechanisms of disease in bone marrow failure and myelodysplastic syndromes and is also working to develop novel therapeutics.
The conversation will focus on managing the condition from diagnosis to treatment. Questions related to all aspects of myelodysplastic syndromes and related conditions are welcome.